Paliperidone-Associated Sialorrhea: A Case Report With Review of Current Literature.

Purpose/background: Antipsychotic-associated sialorrhea is a problematic adverse effect with potentially negative consequences on quality of life and medication adherence. While clozapine is the antipsychotic that is most associated with sialorrhea, there have been published reports of other second-generation antipsychotics associated with sialorrhea, including aripiprazole, olanzapine, quetiapine, and risperidone. Although drooling is mentioned within the package insert for paliperidone, to date there have been minimal published reports in which paliperidone is implicated as the offending agent.

A clinical study of visualization on depressed white blood cell count in medical patients.

This psychoneuroimmunological study examined the effects of visualization, or mental imagery, on immune system response, specifically, on depressed white blood cell (WBC) count in 20 medical patients. Subjects were 10 females and 10 males and included medical patients diagnosed with cancer, AIDS, viral infections, and other medical problems associated with depressed WBC count. Results indicated significant increases in WBC count for all patients over a 90-day period, after a predicted initial decrease in WBC count.

An HMG-I protein from human endothelial cells apparently is secreted and impairs activation of Hageman factor (factor XII).

A highly purified protein from lysates of human umbilical vein endothelial cells (HUVECs) inhibited the activation of factor XII [Hageman factor (HF)] and removed factor XIIa from an activating surface, thus impairing HF-dependent coagulation and kinin-releasing activities. Two tryptic peptides from this protein had 100% identity with amino acids 31-44 and 89-101 of a nonhistone DNA-binding protein known as high-mobility group protein (HMG-I). In specific antibody experiments, the clot-inhibiting property in purified lysate protein from HUVECs was associated with HMG-I.

Asymmetric angioneurotic edema associated with thrombolysis for acute stroke.

We present a case of acute asymmetric angioneurotic edema associated with the use of recombinant tissue plasminogen activator (rtPA) for acute ischemic stroke. rtPA was administered for an acute ischemic stroke in accordance with the recently reported National Institute of Neurological Disorders and Stroke protocol, after which marked asymmetric angioedema requiring upper-airway control developed. Although atypical and anaphylactoid reactions have been reported with the use of rtPA for acute myocardial infarction, to our knowledge this is the first case report of asymmetric angioedema associated with the use of rtPA for acute ischemic stroke.